Company news

Agios Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

November 4, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

October 30, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

October 22, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

October 16, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

September 10, 2024

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

September 4, 2024

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

August 5, 2024

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

July 31, 2024

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

July 31, 2024

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

July 17, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

June 14, 2024

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8: 40 am ET

June 5, 2024

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

June 2, 2024

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 29, 2024

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

May 27, 2024

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

May 13, 2024

Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

May 5, 2024

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

May 2, 2024

Agios Reports Business Highlights and First Quarter 2024 Financial Results

May 1, 2024

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

April 17, 2024

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

April 8, 2024

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

March 4, 2024

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

February 21, 2024

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 14, 2024

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

February 1, 2024

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

January 7, 2024

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

January 2, 2024

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

January 1, 2024

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

December 8, 2023

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

November 19, 2023

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

November 1, 2023

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

November 1, 2023

Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

October 18, 2023

Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

August 28, 2023

Agios Reports Business Highlights and Second Quarter 2023 Financial Results

August 2, 2023

Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

August 2, 2023

Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023

July 12, 2023

Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response

June 25, 2023

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

June 4, 2023

Agios Appoints Catherine Owen to Board of Directors

May 24, 2023

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

May 10, 2023

Agios Reports Business Highlights and First Quarter 2023 Financial Results

May 3, 2023

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023

April 24, 2023

Agios Appoints Jeffrey Capello to Board of Directors

April 18, 2023

Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023

April 12, 2023

Agios Publishes 2023 Environmental, Social and Governance (ESG) Report

April 2, 2023

Agios to Participate in March Investor Conferences

March 1, 2023

Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day

February 27, 2023

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

February 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.